Thus, the anorexigenic action of TriMetChalc in the ob/ob mice is of interest in the perspective of the future development of TriMetChalc as an anti-obesity drug, since human obesity is characterized by leptin resistance [21]. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.